SignalFDA/Bio

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript

Rocket Pharmaceuticals discusses Danon Disease program update with RP-A501 pivotal trial and preliminary clinical data.

What changed

Rocket Pharmaceuticals discusses Danon Disease program update with RP-A501 pivotal trial and preliminary clinical data.

Why it matters

Rocket Pharmaceuticals discusses Danon Disease program update with RP-A501 pivotal trial and preliminary clinical data. — impact context not separately stored; see What changed.

Sources

seekingalpha